- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EVERSANA Announces Real-World Data Agreement with Janssen
Analytic work will drive regulatory grade RWD studies and therapeutic evidence to improve patient outcomes.
EVERSANA today announced an agreement with Janssen Research & Development, LLC (Janssen) to transform clinical data into the much-needed evolution of chronic disease care through real-word data (RWD), data science analysis and regulatory-grade studies. The collaboration between EVERSANA’s RWD Solution team and the Janssen Research & Development Data Science team will help drive evidence-based development of Janssen therapies, treatments, and patient support models.
The agreement will drive a deeper understanding and enhance the design of clinical trials through regulatory-grade, auditable determination of clinical endpoints, thus enabling studies that can reduce clinical trial timelines and offer important signals about how therapies perform in real world settings.
Read more about the new agreement here.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
